Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT06797869 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

A Research Study to Investigate the Effects of CagriSema Compared to Placebo in People With Type 2 Diabetes and Painful Diabetic Peripheral Neuropathy

Name: A Research Study to Investigate the Effects of CagriSema Compared to Placebo in People With Type 2 Diabetes and Painful Diabetic Peripheral Neuropathy — clinical trial record (NCT06797869)
Creator: DataLookout
License: https://creativecommons.org/licenses/by/4.0/

StatusCompleted

PhasePhase 2

SponsorNovo Nordisk A/S

Started2025-01-29

View on ClinicalTrials.gov ↗

This study will look at the effects of CagriSema in people with both type 2 diabetes and painful diabetic peripheral neuropathy, compared to placebo. Participants will either get an active medicine or a "dummy" medicine (placebo). Which treatment participants get is decided by chance. In this study the active, investigational medicine is called CagriSema. Doctors cannot yet prescribe CagriSema. For each participant, the study will last for about 10 months.

Amendment history 2 changes detected by DataLookout

2026-09-11

Trial completed

2026-09-11

Primary completion confirmed: June 2026 (last estimated August 2026)

Trial Details

NCT Number	NCT06797869
Lead Sponsor	Novo Nordisk A/S
Conditions	Diabetes Mellitus, Type 2, Diabetic Peripheral Neuropathy
Enrollment	142 participants
Start Date	2025-01-29
Primary Completion	2026-06-26 (estimated)
Study Completion	2026-08-05 (estimated)
Updated on ClinicalTrials.gov	2026-09-10